Table 6.
Guideline statements on DAPT usage.
| Disease State | ESC 2017 DAPT | ACC/AHA 2016 DAPT |
|---|---|---|
| ACS (Medical therapy, BMS or DES) | 12 months (I-A) 6 months in patients with high bleeding risk (II a-B) >12 months may be considered in patients with prior MI at low bleeding risk (II b-B) |
At least 12 months (I-B) 6 months in patients with high bleeding risk (II b-C) >12 months may be reasonable in patients at low bleeding risk (II b-A) |
| Stable CAD and BMS | 6 months (I-A) In patients with high bleeding risk, 1 month (II b-C) or 3 months (II a-B) |
At least 1 month (I-A) |
| Stable CAD and DES | 6 months (I-A) In patients with high bleeding risk, 1 month (II b-C) or 3 months (II a-B) |
At least 6 months (I-B) |